{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:29:39Z","timestamp":1760189379140,"version":"3.44.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.thromres.2014.05.013","type":"journal-article","created":{"date-parts":[[2014,5,13]],"date-time":"2014-05-13T15:18:17Z","timestamp":1399994297000},"page":"227-233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Treatment of patients with acute deep vein thrombosis and\/or pulmonary embolism: Efficacy and safety of non-VKA oral anticoagulants in selected populations"],"prefix":"10.1016","volume":"134","author":[{"given":"Paolo","family":"Prandoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2014.05.013_bb0005","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/archinte.1991.00400050081016","article-title":"A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study","volume":"151","author":"Anderson","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.thromres.2014.05.013_bb0010","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1160\/TH07-03-0212","article-title":"Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality","volume":"98","author":"Cohen","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.05.013_bb0015","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1160\/TH04-05-0323","article-title":"Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients","volume":"93","author":"Vaitkus","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.05.013_bb0020","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(11)61904-1","article-title":"Pulmonary embolism and deep vein thrombosis","volume":"379","author":"Goldhaber","year":"2012","journal-title":"Lancet"},{"author":"National Institute for Health and Clinical Excellence","key":"10.1016\/j.thromres.2014.05.013_bb0375"},{"key":"10.1016\/j.thromres.2014.05.013_bb0030","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/1358863X12449363","article-title":"Prevalence and economic burden of pulmonary embolism in Germany","volume":"17","author":"Kroger","year":"2012","journal-title":"Vasc Med"},{"key":"10.1016\/j.thromres.2014.05.013_bb0035","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3324\/haematol.10516","article-title":"The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients","volume":"92","author":"Prandoni","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2014.05.013_bb0040","first-page":"475","article-title":"Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations","volume":"13","author":"Spyropoulos","year":"2007","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.thromres.2014.05.013_bb0045","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.thromres.2007.08.009","article-title":"Factors associated with the timing of diagnosis of venous thromboembolism: results from the MASTER registry","volume":"121","author":"Ageno","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2014.05.013_bb0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.thromres.2004.04.007","article-title":"The impact of venous thrombosis on quality of life","volume":"114","author":"van Korlaar","year":"2004","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2014.05.013_bb0055","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1056\/NEJMoa032274","article-title":"Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism","volume":"350","author":"Pengo","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.05.013_bb0060","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1093\/eurheartj\/ehn310","article-title":"Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)","volume":"29","author":"Torbicki","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.thromres.2014.05.013_bb0065","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1146\/annurev-med-062209-095159","article-title":"Novel oral Factor Xa and thrombin inhibitors in the management of thromboembolism","volume":"62","author":"Eriksson","year":"2011","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.thromres.2014.05.013_bb0070","first-page":"51","article-title":"Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism","volume":"4","author":"Kneeland","year":"2010","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.thromres.2014.05.013_bb0075","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(60)92299-6","article-title":"Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial","volume":"1","author":"Barritt","year":"1960","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2014.05.013_bb0080","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(85)90459-3","article-title":"Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis","volume":"2","author":"Lagerstedt","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2014.05.013_bb0085","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199211193272103","article-title":"Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis","volume":"327","author":"Brandjes","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.05.013_bb0090","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/archinte.160.6.761","article-title":"Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study","volume":"160","author":"Heit","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.thromres.2014.05.013_bb0095","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jama.293.6.681","article-title":"Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial","volume":"293","author":"Fiessinger","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2014.05.013_bb0380","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1056\/NEJMoa064247","article-title":"Idraparinux versus standard therapy for venous thromboembolic disease","volume":"357","author":"van Gogh Investigators","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.05.013_bb0105","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.05.013_bb0110","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","article-title":"Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","volume":"129","author":"Schulman","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2014.05.013_bb0115","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"The EINSTEIN Investigators","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.05.013_bb0120","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"The EINSTEIN\u2013PE Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.05.013_bb0125","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1477-9560-11-13","article-title":"Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism","volume":"11","author":"Prins","year":"2013","journal-title":"Thromb J"},{"key":"10.1016\/j.thromres.2014.05.013_bb0130","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.05.013_bb0385","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"The Hokusai-VTE Investigators","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.05.013_bb0140","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.05.013_bb0145","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.05.013_bb0150","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMoa1210384","article-title":"Low-dose aspirin for preventing recurrent venous thromboembolism","volume":"367","author":"Brighton","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.05.013_bb0155","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa1114238","article-title":"Aspirin for preventing the recurrence of venous thromboembolism","volume":"366","author":"Becattini","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.05.013_bb0160","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1182\/blood-2007-06-096545","article-title":"Venous thrombosis in the elderly: more questions than answers","volume":"110","author":"Silverstein","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.05.013_bb0165","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/11586730-000000000-00000","article-title":"Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment","volume":"28","author":"Samama","year":"2011","journal-title":"Drugs Aging"},{"key":"10.1016\/j.thromres.2014.05.013_bb0170","first-page":"1046","article-title":"Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE)","volume":"91","author":"L\u00f3pez-Jim\u00e9nez","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2014.05.013_bb0175","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1160\/TH08-04-0255","article-title":"Venous thromboembolism in the elderly. A community-based perspective","volume":"100","author":"Spencer","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.05.013_bb0180","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jvs.2005.05.053","article-title":"Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs","volume":"42","author":"Caprini","year":"2005","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.thromres.2014.05.013_bb0185","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.2165\/11635730-000000000-00000","article-title":"New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function","volume":"72","author":"Poulsen","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.thromres.2014.05.013_bb0190","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.thromres.2011.03.002","article-title":"Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep\u00ae in Renal Insufficiency Study (IRIS)","volume":"128","author":"Leizorovicz","year":"2011","journal-title":"Thromb Res"},{"author":"Bayer Pharma AG","key":"10.1016\/j.thromres.2014.05.013_bb0390"},{"author":"Boehringer Ingelheim International GmbH","key":"10.1016\/j.thromres.2014.05.013_bb0395"},{"author":"Bristol-Myers Squibb, Pfizer EEIG","key":"10.1016\/j.thromres.2014.05.013_bb0400"},{"key":"10.1016\/j.thromres.2014.05.013_bb0210","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2141.2004.05292.x","article-title":"Management of thrombosis in cancer: primary prevention and secondary prophylaxis","volume":"128","author":"Lee","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2014.05.013_bb0215","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00005792-199909000-00001","article-title":"Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data","volume":"78","author":"Levitan","year":"1999","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.thromres.2014.05.013_bb0220","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/cncr.25714","article-title":"Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis","volume":"117","author":"Lyman","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.thromres.2014.05.013_bb0225","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2014.05.013_bb0230","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-11-21","article-title":"Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies","volume":"11","author":"Prins","year":"2013","journal-title":"Thromb J"},{"key":"10.1016\/j.thromres.2014.05.013_bb0235","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/01.CIR.0000078468.11849.66","article-title":"The epidemiology of venous thromboembolism","volume":"107","author":"White","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2014.05.013_bb0240","first-page":"506","article-title":"Occurrence of pulmonary embolism among 260 in-patients of acute geriatric department aged 65+ years in 2005\u20132010","volume":"25","author":"Weberova","year":"2012","journal-title":"Adv Gerontol"},{"key":"10.1016\/j.thromres.2014.05.013_bb0245","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1111\/j.1532-5415.2010.03032.x","article-title":"Fighting against age discrimination in clinical trials","volume":"58","author":"Cherubini","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.thromres.2014.05.013_bb0250","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1161\/CIRCULATIONAHA.110.007864","article-title":"Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation","volume":"124","author":"Poli","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2014.05.013_bb0255","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin Pharmacokinet"},{"issue":"455","key":"10.1016\/j.thromres.2014.05.013_bb0405","first-page":"PP-MO-407","article-title":"Effects of age and gender on the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) of apixaban","volume":"7","author":"Frost","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.05.013_bb0265","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1016\/j.thromres.2010.07.015","article-title":"Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults","volume":"126","author":"Samama","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2014.05.013_bb0270","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1185\/03007990802361499","article-title":"Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects","volume":"24","author":"Kubitza","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.thromres.2014.05.013_bb0275","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1160\/TH12-03-0209","article-title":"Management consensus guidance for the use of rivaroxaban - an oral, direct Factor Xa inhibitor","volume":"108","author":"Turpie","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.05.013_bb0280","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.4161\/cbt.10.10.13236","article-title":"Use of dabigatran etexilate to reduce breast cancer progression","volume":"10","author":"Defeo","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.thromres.2014.05.013_bb0285","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1538-7836.2012.04693.x","article-title":"A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer","volume":"10","author":"Levine","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.05.013_bb0290","doi-asserted-by":"crossref","first-page":"e195S","DOI":"10.1378\/chest.11-2296","article-title":"Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Kahn","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2014.05.013_bb0295","doi-asserted-by":"crossref","first-page":"e227S","DOI":"10.1378\/chest.11-2297","article-title":"Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Gould","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2014.05.013_bb0300","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/jth.12150","article-title":"Clot resolution after 3weeks of anticoagulant treatment of pulmonary embolism: comparison of computed tomography and perfusion scintigraphy","volume":"11","author":"van Es","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.05.013_bb0305","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/j.thromres.2012.11.029","article-title":"Whole blood clots are more resistant to lysis than plasma clots - greater efficacy of rivaroxaban","volume":"131","author":"Varin","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2014.05.013_bb0310","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1160\/TH12-11-0821","article-title":"Resolution of giant left atrial appendage thrombus with rivaroxaban","volume":"109","author":"Hammerstingl","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.05.013_bb0315","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.amjcard.2004.06.010","article-title":"Fate of left atrial thrombi in patients with atrial fibrillation determined by transesophageal echocardiography and cerebral magnetic resonance imaging","volume":"94","author":"Bernhardt","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.thromres.2014.05.013_bb0320","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1093\/eurheartj\/ehs258","article-title":"Pulmonary embolism: risk assessment and management","volume":"33","author":"Konstantinides","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.thromres.2014.05.013_bb0325","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1161\/CIRCULATIONAHA.107.726232","article-title":"Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry","volume":"117","author":"Laporte","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2014.05.013_bb0330","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1378\/chest.108.4.978","article-title":"Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy","volume":"108","author":"Stein","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2014.05.013_bb0335","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0735-1097(97)00319-7","article-title":"Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry","volume":"30","author":"Kasper","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2014.05.013_bb0340","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.amjmed.2011.10.015","article-title":"Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused","volume":"125","author":"Stein","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.thromres.2014.05.013_bb0345","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1161\/CIRCULATIONAHA.105.592592","article-title":"Massive pulmonary embolism","volume":"113","author":"Kucher","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2014.05.013_bb0350","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa1302097","article-title":"Fibrinolysis for patients with intermediate-risk pulmonary embolism","volume":"370","author":"Meyer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.05.013_bb0355","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/clc.22216","article-title":"Safe-dose thrombolysis plus rivaroxaban for moderate and severe pulmonary embolism: drip, drug, and discharge","volume":"37","author":"Sharifi","year":"2014","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.thromres.2014.05.013_bb0360","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/PPA.S24752","article-title":"A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence","volume":"6","author":"Barbosa","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.thromres.2014.05.013_bb0365","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.05.013_bb0370","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1160\/TH13-03-0243","article-title":"Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis","volume":"110","author":"Bamber","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.05.013_bb0410","first-page":"1163","article-title":"Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism","volume":"120","author":"Prins","year":"2012","journal-title":"Blood (ASH Annu Meet Abstr)"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814002783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814002783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:37:11Z","timestamp":1758735431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384814002783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0049384814002783"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2014.05.013","relation":{},"ISSN":["0049-3848"],"issn-type":[{"type":"print","value":"0049-3848"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of patients with acute deep vein thrombosis and\/or pulmonary embolism: Efficacy and safety of non-VKA oral anticoagulants in selected populations","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2014.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}